|
ИСТИНА |
Войти в систему Регистрация |
ИПМех РАН |
||
Psychopharmacogenetic analysis in the structure of a multifactorial personalized approach to the patientстатья
Статья опубликована в высокорейтинговом журнале
Статья опубликована в журнале из списка Web of Science и/или ScopusДата последнего поиска статьи во внешних источниках: 3 февраля 2022 г.
- Авторы: Kutovoy D., Zakharova N., Nizamutdinov I., Ilinsky V., Reznik A., Kostyuk G.
- Журнал: European Psychiatry
- Том: 56
- Номер: S1
- Год издания: 2019
- Издательство: Cambridge University Press
- Местоположение издательства: United Kingdom
- Первая страница: S576
- Аннотация: Background and aims.– The efficacy and safety of psychopharmacotherapy are one of the most discussed issues of psychiatry. Prevalence rates of psychopharmacotherapy inefficiency are relatively constant, and vary from 30% to 60–75%. Methods.– Pharmacogenetic testing seem to be an useful approach to increase therapy efficiency rate. Databases of genetic markers involved in pharmacokinetics and pharmacodynamics are constantly updated, recommendations for genetic testing are provided in some drug labels. Psychopharmacogenetics is a promising area of work for the Alekseev Psychiatric Clinical Hospital No1. Using the ontology PsyGenCheck, a psychopharmacogenetic test was performed for 14 patients (10 men, 4 women, 18–40 years old) with a catamnesis 1–36 months after genotyping, on customized Global Screening Array microchips. Results.– The results of this analysis have been confirmed in practice - the intolerance of some drugs has been revealed, the dosage of others has been adjusted. Preliminary calculations indicate a reduction in the economic burden on the budget by about 2.5 times when conducting a test with high-performance genotyping. Conclusions.– Due to the choice of the optimal dose of an individually suitable drug, compliance increases, the duration of inpatient treatment decreases, there are no side effects that require additional examination and treatment, the probability of a positive response to the drug doubles, and the duration of high-quality remission increases threefold.
- Добавил в систему: Костюк Георгий Петрович